The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients.

Learn why doctors are using Ozempic to address insulin resistance, fatty liver, and cardiovascular risk, not just obesity.

New research suggests that drugs like Ozempic and Wegovy might trigger more than just a slimmer waistline. Many users have reported digestive issues while taking the medications, including nausea, ...

As Ozempic reshapes the weight-loss landscape, doctors say there’s a crucial part of the story many users overlook until it’s too late.

A cardiologist's assertion that Ozempic is a "cardiometabolic medicine" rather than just a weight-loss trend has sparked ...

Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes. The approval makes ...

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...